Thomas A. Danne

Thomas A. Danne

Janusz Korczak Allee 12
Hannover, NI 30173, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 250 publications

LDL hypercholesterolemia in children: genetic influence and response to lifestyle advice - follow-up of the Fr1dolin-trial.

LDL hypercholesterolemia in children: genetic influence and response to lifestyle advice - follow-up of the Fr1dolin-trial.

Journal: Lipids in health and disease

Published: May 14, 2026

Adults with type 1 diabetes define what matters to them in stem-cell derived islet cell therapy.

Adults with type 1 diabetes define what matters to them in stem-cell derived islet cell therapy.

Journal: Nature medicine

Published: February 18, 2026

CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.

CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.

Journal: Cardiovascular diabetology

Published: January 26, 2026

International clinical opinion on transparency, standardisation, and calibration alignment in the performance evaluation of systems for continuous glucose monitoring.

International clinical opinion on transparency, standardisation, and calibration alignment in the performance evaluation of systems for continuous glucose monitoring.

Journal: Diabetes, obesity & metabolism

Published: December 05, 2025

Optimizing Type 1 Diabetes Screening in People With Family History: A German Perspective.

Optimizing Type 1 Diabetes Screening in People With Family History: A German Perspective.

Journal: Journal of diabetes science and technology

Published: November 10, 2025

Automated insulin delivery (AID) systems, physical activity and sports in type 1 diabetes mellitus: joint guidelines of the DDG and ÖDG

Automated insulin delivery (AID) systems, physical activity and sports in type 1 diabetes mellitus: joint guidelines of the DDG and ÖDG

Journal: Wiener klinische Wochenschrift

Published: October 14, 2025

Long-Term Glycemic Outcomes in Pediatric Type 1 Diabetes: A 2-Year Real-World Analysis of Different Automated Insulin Delivery Systems Generations.

Long-Term Glycemic Outcomes in Pediatric Type 1 Diabetes: A 2-Year Real-World Analysis of Different Automated Insulin Delivery Systems Generations.

Journal: Diabetes technology & therapeutics

Published: September 15, 2025

Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology.

Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology.

Journal: The lancet. Diabetes & endocrinology

Published: August 08, 2025

Continuous Glucose Monitoring Metrics and Continuous Glucose Monitoring-Based Hypoglycemia, Including Duration, in Individuals with Type 1 Diabetes Switching to Once-Weekly Insulin Icodec: A Post Hoc Evaluation of ONWARDS 6.

Continuous Glucose Monitoring Metrics and Continuous Glucose Monitoring-Based Hypoglycemia, Including Duration, in Individuals with Type 1 Diabetes Switching to Once-Weekly Insulin Icodec: A Post Hoc Evaluation of ONWARDS 6.

Journal: Diabetes technology & therapeutics

Published: July 31, 2025

Evaluating the long-term effectiveness of a structured telehealth obesity program in children and adolescents: A retrospective matched-control study.

Evaluating the long-term effectiveness of a structured telehealth obesity program in children and adolescents: A retrospective matched-control study.

Journal: Obesity pillars

Published: July 30, 2025

Correction to: Safety and Effectiveness of Glargine 300 U/ml After Switching from Basal Insulins in Patients with Type 1 Diabetes: COMET-T Study.

Correction to: Safety and Effectiveness of Glargine 300 U/ml After Switching from Basal Insulins in Patients with Type 1 Diabetes: COMET-T Study.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: July 14, 2025

Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.

Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.

Journal: Lancet (London, England)

Published: July 07, 2025

Showing 1-12 of 250

Last Updated: 09/26/2026